ABSTRACT
BACKGROUND: Malaria is a major public health problem representing 2.3% of the overall global disease burden. The cost of treatment of malaria continues to rise as older drugs and insecticides become less effective and are replaced by more effective, but also more expensive products. METHODS: A post-hoc pharmacoeconomic analysis (direct and indirect costs only) of three antimalarials, chloroquine, mefloquine and co-artemether, was carried out to address the problem of switch to a more expensive first-line antimalarial in the face of growing chloroquine resistance. RESULTS: From the perspective of a large public hospital, it was seen that in an area of high grade chloroquine resistance, the total expenditure on patients who fail chloroquine would exceed the excess expenditure on mefloquine when the RII + RIII resistance exceeded 9%. CONCLUSIONS: Switch to a more expensive drug like mefloquine as a first-line option would be cost-effective when the moderate-severe chloroquine resistance exceeded 9%.
Subject(s)
Antimalarials/economics , Artemisinins/economics , Chloroquine/economics , Clinical Trials as Topic/economics , Cost-Benefit Analysis , Drug Combinations , Economics, Pharmaceutical , Female , Fluorenes/economics , Hospitalization/economics , Humans , India , Malaria, Falciparum/drug therapy , Male , Mefloquine/economics , Sesquiterpenes/economicsABSTRACT
OBJECTIVES: The present study compared the diagnostic and prognostic utility of two rapid tests the (Paracheck and OptiMal) versus conventional smear microscopy. METHODS: Using two independent microscopists we carried out the three tests in 31 adult cases of smear positive, acute, uncomplicated Plasmodium falciparum malaria. All three tests were done pretreatment, and on Days 8, 15 and 29. RESULTS: Compared to microscopy, the Paracheck had a sensitivity of 100%, while the OptiMal had a sensitivity of 83.7%. The lower sensitivity of OptiMal resulted from misidentification by both microscopists of 6/31 cases as Plasmodium vivax. As a follow up tool, the OptiMal was better than Paracheck, due to the earlier disappearance of the parasite LDH. Also in the Paracheck, between microscopists, there was a significant difference in reading the tests, on Days 8 and 15. CONCLUSION: Our study reiterates, the continued utility of conventional smear microscopy.
Subject(s)
Adolescent , Adult , Animals , Cross-Sectional Studies , Female , Humans , L-Lactate Dehydrogenase/analysis , Malaria, Falciparum/diagnosis , Male , Mass Screening/methods , Middle Aged , Plasmodium falciparum/enzymology , Predictive Value of Tests , Proteins/analysis , Protozoan Proteins/analysis , Reagent Kits, Diagnostic , Sensitivity and Specificity , Serologic Tests/methodsSubject(s)
Adolescent , Cerebellar Diseases/parasitology , Humans , Malaria, Falciparum/complications , Male , SyndromeABSTRACT
OBJECTIVES: To analyze the relapse pattern of Plasmodium vivax in the city of Mumbai. METHODS: 283 cases of smear positive vivax malaria were treated with full dose (25 mg/kg) chloroquine and were asked to follow up for at least one year. None of the patients received primaquine. RESULTS: Of the 150 cases who followed up for at least one year, 19 relapsed, 17/19 relapsed within the first 6 months; indicating that the relapse pattern in the city is predominantly of the tropical or Chesson strain type. CONCLUSIONS: Vivax malaria patients should be monitored for at least six months. Those who do relapse should receive treatment with full dose chloroquine and 14 days of primaquine treatment.
Subject(s)
Adolescent , Adult , Age Distribution , Aged , Animals , Antimalarials/administration & dosage , Chloroquine/administration & dosage , Female , Follow-Up Studies , Humans , Incidence , India/epidemiology , Malaria, Vivax/diagnosis , Male , Middle Aged , Plasmodium vivax/isolation & purification , Prospective Studies , Recurrence , Risk Factors , Sex Distribution , Treatment OutcomeABSTRACT
The effect of single oral dose of 1 gm gugulipid was studied on bioavailability of single oral dose of propranolol (40 mg) and diltiazem (60 mg) in 10 and 7 normal healthy male volunteers respectively. It was a randomised within group crossover study. Blood samples were collected at hourly intervals upto 8 hrs. Gugulipid significantly reduced (P < .01) peak plasma concentration (Cmax) and area under curve (AUC 0-8 hrs) of both the drugs in normal volunteers. Such interaction in patients receiving propanolol or diltiazem with gugulipid may lead to diminished efficacy or nonresponsiveness due to significant reduction in bioavailability.
Subject(s)
Administration, Oral , Adult , Hypolipidemic Agents/pharmacology , Biological Availability , Commiphora , Cross-Over Studies , Diltiazem/pharmacokinetics , Humans , Male , Plant Extracts/pharmacology , Plant Gums , Propranolol/pharmacokineticsABSTRACT
Poor patient compliance is one of the major causes of non responsiveness to antiepileptic drug therapy. Compliance is mostly assessed by self reporting, pill counting and plasma drug level estimation. However, none of them is fool proof. Subtherapeutic plasma drug levels can be due to poor compliance or need for higher dosage. Therefore, in the present study, 20 adult non responsive epileptic patients showing subtherapeutic plasma phenytoin levels inspite of receiving standard phenytoin therapy and history of good compliance were admitted in the clinical pharmacology ward and received supervised drug treatment for five days after which plasma phenytoin levels in 14 patients increased to therapeutic range. All except one (i.e. 9 out of 10) patients showing phenytoin levels < 5 ug/ml inspite of phenytoin dosage of > 300 mg/d and history of good compliance were found to be noncompliant. Hence adult patient receiving greater than or equal to 300 mg/day phenytion and showing phenytoin levels less than or equal to 5 ug/ml should be investigated for possible noncompliance before altering their dosage schedules.
Subject(s)
Adolescent , Adult , Epilepsy, Tonic-Clonic/drug therapy , Humans , Male , Middle Aged , Patient Compliance , Phenytoin/bloodABSTRACT
Phenytoin is widely used for the treatment of generalized tonic clonic and partial seizures. Monitoring of serum phenytoin levels is essential to optimize therapy. Of 320 patients monitored, 190 patients whose seizures were uncontrolled were followed up before and after dosage adjustment was carried out. Plasma phenytoin estimation was done by HPLC method. Of all the patients receiving the drug, 20% and 8% of patients were finally on dosages requiring 50 and 25 mg fraction administration respectively. Administration of 100 mg fractions resulted in either loss of seizure control or toxicity. This emphasizes the need for providing tablets of 25 mg strength, presently not available in this country.
Subject(s)
Adolescent , Adult , Child , Child, Preschool , Dose-Response Relationship, Drug , Electroencephalography/drug effects , Epilepsy, Tonic-Clonic/drug therapy , Female , Humans , Male , Middle Aged , Phenytoin/administration & dosageABSTRACT
Asparagus racemosus (Shatavari) is used in Ayurveda for dyspepsia (amlapitta) and as a galactogogue. It was hence compared with a modern drug, metoclopramide, which is used in dyspepsia to reduce gastric emptying time. Gastric emptying half- time (GE t1/2) was studied in 8 healthy male volunteers using a cross-over design. The basal GE t1/2 in volunteers was 159.9 +/- 45.9 min (mean +/- SD) which was reduced to 101 +/- 40.8 min by Shatavari (p less than 0.001) and to 85.3 +/- 21.9 by metoclopramide (p less than 0.001). Metoclopramide and Shatavari did not differ significantly in their effects.